There is uncertainty whether current strategies for providing CVD risk scores  affect CVD events .
Providing CVD risk scores may slightly reduce CVD risk factor levels and may increase preventive medication prescribing in higher-risk people without evidence of harm .
BACKGROUND The current paradigm for cardiovascular disease ( CVD ) emphasises absolute risk assessment to guide treatment decisions in primary prevention .
Although the derivation and validation of multivariable risk assessment tools , or CVD risk scores , have attracted considerable attention , their effect on clinical outcomes is uncertain .
OBJECTIVES To assess the effects of evaluating and providing CVD risk scores in adults without prevalent CVD on cardiovascular outcomes , risk factor levels , preventive medication prescribing , and health behaviours .
Effect of the statin choice encounter decision aid in Spanish patients with type 2 diabetes: A randomized trial.
OBJECTIVE Statin choice , an encounter decision aid ( DA ) , was developed in the USA to facilitate shared decision making between patients and clinicians about the use of statins to reduce cardiovascular risk . We aim ed to assess the efficacy of this DA , compared to usual primary care , in Spanish patients with type 2 diabetes . METHODS Cluster r and omized trial with 29 clinicians and 168 patients .  Knowledge of statins , cardiovascular risk perception , decisional conflict , anxiety and satisfaction with the decision making process were assessed immediately after intervention , and self-reported adherence at three months . RESULTS Intervention significantly improved knowledge ( p=0.01 ) , perception of the 10-year risk of myocardial infa rct ion without ( p=0.01 ) and with statins ( p=0.08 ) , and satisfaction ( p=0.01 ) . There were no significant differences in decisional conflict , anxiety , consultation time or adherence , although more intervention patients reported taking all pills during the last week ( 92.7 % vs. 81 % ; p=0.19 ) . CONCLUSION The statin choice DA improved the quality of decision making about statins . PRACTICE IMPLICATION S This trial contributes to the body of evidence substantiating the efficacy of statin choice and extending it to Spanish clinicians and their patients with type 2 diabetes . TRIAL REGISTRATION This trial is registered with the European Union Clinical Trials Register ( EudraCT : 2010 - 023912 - 14 )
There is uncertainty whether current strategies for providing CVD risk scores  affect CVD events .
Providing CVD risk scores may slightly reduce CVD risk factor levels and may increase preventive medication prescribing in higher-risk people without evidence of harm .
BACKGROUND The current paradigm for cardiovascular disease ( CVD ) emphasises absolute risk assessment to guide treatment decisions in primary prevention .
Although the derivation and validation of multivariable risk assessment tools , or CVD risk scores , have attracted considerable attention , their effect on clinical outcomes is uncertain .
OBJECTIVES To assess the effects of evaluating and providing CVD risk scores in adults without prevalent CVD on cardiovascular outcomes , risk factor levels , preventive medication prescribing , and health behaviours .